On July 20, SELLAS Life Sciences fell 8.85% in regular trading, trading at $12.075 USD/share, with Turnover of $27.39 million.

Within the Biotechnology sector where SELLAS Life Sciences belongs, the overall sector showed mixed performance. Among individual stocks, AbbVie up 0.29%, Amgen up 0.14%, Vertex Pharmaceuticals up 0.42%, Gilead Sciences down 0.42%, Regeneron Pharmaceuticals down 0.6%.

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies. Its lead product candidate is Galinpepimut-S (GPS), currently in Phase 3 clinical trials for the treatment of acute myeloid leukemia, along with SLS009, a highly selective CDK9 inhibitor.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)